Table 2.
Adverse Events Observed Throughout the Study Period, by Treatment Group
| Adverse Event | No. (%) | |
|---|---|---|
| Placebo (n = 21) | Dupilumab (n = 19) | |
| Injection site reaction | 0 (0.0) | 0 (0.0) |
| Conjunctivitis | 2 (9.5) | 0 (0.0) |
| Bacterial pneumonia | 1 (4.8) | 2 (10.5) |
| Herpes viral infection | 0 (0.0) | 0 (0.0) |
| Eosinophiliaa | 1 (4.8) | 5 (26.3) |
| Hyper-eosinophilic syndrome | 0 (0.0) | 0 (0.0) |
| Other infections | 2 (9.5) | 4 (21.1) |
| Cumulative | 6 | 11 |
Other infections included Clostridioides difficile infection (1), bacteremia (2), urinary tract infection (2), and oral candidiasis (1).
a
Eosinophilia was defined as an absolute eosinophil count >0.6 k/µL at ≥1 measurement throughout the study period. Difference between treatment groups was not statistically significant with Fisher exact P = .09.